肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2021 中国专家共识：复发性宫颈癌¹²⁵I粒子植入治疗

2021-11-09 中国肿瘤科相关专家小组（统称） Front Oncol

妇科肿瘤复发性宫颈癌粒子植入治疗

复发性宫颈癌的治疗方式有限，且这些患者的预后非常差。在手术或放疗后剂量增加或挽救治疗的情况下，粒子植入可能是复发性宫颈癌管理的一个重要组成部分。

中文标题：

2021 中国专家共识：复发性宫颈癌¹²⁵I粒子植入治疗

英文标题：

Chinese Expert Consensus on Iodine 125 Seed Implantation for Recurrent Cervical Cancer in 2021

发布机构：

中国肿瘤科相关专家小组（统称）

发布日期：

2021-11-09

简要介绍：

复发性宫颈癌的治疗方式有限，且这些患者的预后非常差。在手术或放疗后剂量增加或挽救治疗的情况下，粒子植入可能是复发性宫颈癌管理的一个重要组成部分。本文主要讨论了复发性宫颈癌¹²⁵I粒子植入治疗的适应证选择、技术流程、剂量学、辐射防护以及联合全身治疗等。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 中国专家共识：复发性宫颈癌¹²⁵I粒子植入治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=038241c0022851b0, title=2021 中国专家共识：复发性宫颈癌¹²⁵I粒子植入治疗, enTitle=Chinese Expert Consensus on Iodine 125 Seed Implantation for Recurrent Cervical Cancer in 2021, guiderFrom=Front Oncol, authorId=0, author=, summary=复发性宫颈癌的治疗方式有限，且这些患者的预后非常差。在手术或放疗后剂量增加或挽救治疗的情况下，粒子植入可能是复发性宫颈癌管理的一个重要组成部分。, cover=https://img.medsci.cn/2021126/1638799926336_5579292.png, journalId=0, articlesId=null, associationId=747, associationName=中国肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Tue Nov 09 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">复发性宫颈癌的治疗方式有限，且这些患者的预后非常差。在手术或放疗后剂量增加或挽救治疗的情况下，粒子植入可能是复发性宫颈癌管理的一个重要组成部分。本文主要讨论了复发性宫颈癌&sup1;&sup2;⁵I粒子植入治疗的适应证选择、技术流程、剂量学、辐射防护以及联合全身治疗等。</span></p>, tagList=[TagDto(tagId=1983, tagName=妇科肿瘤), TagDto(tagId=119151, tagName=复发性宫颈癌), TagDto(tagId=119152, tagName=粒子植入治疗)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=36, categoryName=妇产科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21053, categoryName=梅斯医学-宫颈癌网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1402, guiderKeyword=宫颈癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3307, appHits=92, showAppHits=0, pcHits=607, showPcHits=3215, likes=0, shares=12, comments=5, approvalStatus=1, publishedTime=Mon Dec 06 22:17:23 CST 2021, publishedTimeString=2021-11-09, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Dec 06 22:17:18 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 04:45:26 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 中国专家共识：复发性宫颈癌¹²⁵I粒子植入治疗.pdf)])
2021 中国专家共识：复发性宫颈癌¹²⁵I粒子植入治疗.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1079238, encodeId=96a510e923888, content=不错👌, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd796394025, createdName=ms5000000312608765, createdTime=Sun Dec 12 12:26:47 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077947, encodeId=ac6510e79473f, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 08 06:58:13 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077595, encodeId=cab310e759564, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Dec 07 07:00:42 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077555, encodeId=e43f10e75550a, content=坚持学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Mon Dec 06 22:48:18 CST 2021, time=2021-12-06, status=1, ipAttribution=)]
    2021-12-12 ms5000000312608765

    不错👌

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1079238, encodeId=96a510e923888, content=不错👌, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd796394025, createdName=ms5000000312608765, createdTime=Sun Dec 12 12:26:47 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077947, encodeId=ac6510e79473f, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 08 06:58:13 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077595, encodeId=cab310e759564, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Dec 07 07:00:42 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077555, encodeId=e43f10e75550a, content=坚持学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Mon Dec 06 22:48:18 CST 2021, time=2021-12-06, status=1, ipAttribution=)]
    2021-12-08 微探

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1079238, encodeId=96a510e923888, content=不错👌, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd796394025, createdName=ms5000000312608765, createdTime=Sun Dec 12 12:26:47 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077947, encodeId=ac6510e79473f, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 08 06:58:13 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077595, encodeId=cab310e759564, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Dec 07 07:00:42 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077555, encodeId=e43f10e75550a, content=坚持学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Mon Dec 06 22:48:18 CST 2021, time=2021-12-06, status=1, ipAttribution=)]
    2021-12-07 微探

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1079238, encodeId=96a510e923888, content=不错👌, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd796394025, createdName=ms5000000312608765, createdTime=Sun Dec 12 12:26:47 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077947, encodeId=ac6510e79473f, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 08 06:58:13 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077595, encodeId=cab310e759564, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Dec 07 07:00:42 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077555, encodeId=e43f10e75550a, content=坚持学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Mon Dec 06 22:48:18 CST 2021, time=2021-12-06, status=1, ipAttribution=)]
    2021-12-06 SR~young海东

    坚持学习

    0

相关指南

2021 欧洲专家共识：一线BRCA/同源重组缺陷检测

国外肿瘤科相关专家小组（统称） · 2021-11-30

《世界卫生组织子宫颈癌癌前病变筛查和治疗指南（第2版）》解读

北京大学人民医院妇科 · 2021-09-20

子宫颈胃型腺癌临床诊治中国专家共识

中国医师协会妇产科医师分会妇科肿瘤专业委员会(学组) · 2021-11-04

PARP抑制剂不良反应管理的中国专家共识

中国抗癌协会妇科肿瘤专业委员会 · 2021-11-01

消除子宫颈癌之HPV疫苗应用广东专家共识

广东省预防医学会宫颈癌防治专业委员会 · 2021-09-30

2021 ACOG临床共识：雌激素依赖性乳腺癌患者泌尿生殖道症状的治疗

美国妇产科医师学会(ACOG,American College of Obstetricians and Gynecologists) · 2021-11-20

拓展阅读

2010 NACB医学实践指南：肝癌、膀胱癌、子宫颈癌、胃癌肿瘤标志物的应用

美国临床生化科学院(NACB,The National Academy of Clinical Biochemistry) · 2010-01-01

2010ESMO临床实践指南：宫颈癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-01

2010 宫颈癌规范化诊治指南

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2010-11-16

2011SOGC 低资源地区宫颈癌的预防

加拿大妇产科医生协会(SOGC,Society of Obstetricians and Gynaecologists of Canada) · 2011-03-01

2011 ESUR指南：宫颈癌MRI分期

欧洲泌尿生殖放射学会(ESUR,European Society of Urogenital Radiology) · 2011-05-10

2011 子宫颈癌诊断指南

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2011-07-01